LASER PHOTOCOAGULATION VERSUS INTRAVITREAL ANTI VEGF AGENTS FOR TREATMENT OF RETINOPATHY OF PREMATURITY | ||||
| Egyptian Journal of Clinical Ophthalmology | ||||
| Article 11, Volume 7, Issue 1, June 2024, Page 87-95 PDF (290.52 K) | ||||
| Document Type: Original articles: include clinical trials, interventional research, Basic researches and clinically relevant laboratory investigations | ||||
| DOI: 10.21608/ejco.2024.361193 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Aldghaimy, A. | ||||
| Ophthalmology dept., Faculty of Medicine, South Valley, Univ., Egypt, | ||||
| Abstract | ||||
| Background: Early birth and various oxygen techniques can cause retinopathy of prematurity (ROP), a widespread childhood visual problem. An aggressive ROP (A-ROP) differs from normal progression. Diode laser replaced cryotherapy. Laser treatment is customary but limited, prompting anti-VEGF research. BEAT-ROP aids anti-VEGF. Aim: Compare efficacy and safety of laser photocoagulation with intravitreal anti-VEGF agents for ROP. Methods: Retrospective study at Qena university hospital, adhering to Helsinki Declaration. Participants had ROP type 1 or AROP, treated with anti-VEGF or laser within 72 hours (or 24 hours for A-ROP) between 2021 and 2024 at Qena University, followed for ≥6 months. ICROP criteria guided diagnosis and classification. Treatment decision involved parental consultation; unfit patients for general anesthesia received anti-VEGF. Patients anticipated to have poor adherence to follow up received antiVEGF. Post-treatment follow-ups evaluated efficacy, with cycloplegic refraction at 6 months. Outcome measures included regression, reactivation, and retinal detachment. Results: Significant differences observed between Anti-VEGF and Laser groups in Zone-I ROP and APROP parameters. No significant variation in sex distribution, gestational age (GA), birth weight, or followup duration in Zone-I. In Zone-II, significant differences in GA, birth weight, and follow-up duration. Anti-VEGF demonstrated superior outcomes in initial regression, reactivation, and retinal detachment. Conclusion: Anti-VEGF therapy, notably Ranibizumab, outperforms laser photocoagulation for ROP treatment in aggressive forms in Zone I. This appears to show better initial regression, lesser reactivation, and lower retinal detachment. Anti-VEGF therapy, and laser photocoagulation for ROP treatment in Zone II appears to show comparable initial regression and retinal detachment but laser show lesser reactivation than Anti-VEGF therapy. Research in clinical practice is needed. | ||||
| Keywords | ||||
| Laser photocoagulation; Intravitreal anti-VEGF agents; Retinopathy of prematurity; Ocular therapy | ||||
|
Statistics Article View: 117 PDF Download: 133 |
||||
